viewGalan Lithium Ltd

Galan Lithium appoints Daniel Jiménez Schuster as an independent non-executive director

He joins Galan at an important time in development of the Candelas project with a maiden resource estimate expected this quarter and a PFS to begin next quarter.

Galan Lithium Ltd - Galan Lithium appoints Daniel Jiménez Schuster to the board as an independent non-executive director
Schuster is a former senior executive with more than 28 years’ experience at a world-leading lithium company based in Chile

Galan Lithium Ltd (ASX:GLN) has appointed Daniel Jiménez Schuster to the company's board as an independent non-executive director.

Schuster is a civil engineer and has worked for Chile-based Sociedad QuÍmica y Minera de Chile (NYSE:SQM) for 28 years.

His last position at SQM was as vice president of sales of lithium, iodine and industrial chemicals where he formulated the commercial strategy and marketing of the company’s industrial products.

During this role, Schuster was responsible for more than US$900 million worth of estimated sales in 2018.

Testament “to the calibre of our projects”

Galan Lithium chairman Nathan McMahon said: “People with Daniel’s experience, particularly in the South American lithium industry, are not easy to find.

“That Daniel agreed to join the Galan board is further testament to the calibre of our projects and the quality of work we have achieved to date.

“Daniel’s experience will assist us greatly at this important time in the development of the Candelas project with the imminent announcement of the mineral resource estimate, the pre-feasibility study slated for commencement during the fourth quarter 2019 and as we potentially transition from explorer to developer.”

Leading lithium consultant

Since leaving SQM Schuster has been a leading consultant to the lithium industry focusing on market intelligence, forecasting and lithium business strategy.

Quick facts: Galan Lithium Ltd

Price: 0.48 AUD

Market: ASX
Market Cap: $115.23 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Bionomics' positive pharmacokinetic results confirms it can begin second...

Bionomics Limited (ASX:BNO) (OTCQB:BNOEF) Executive Chairman Errol De Souza tells Proactive tells Proactive the Adelaide, Australia- based biopharmaceutical company has received positive pharmacokinetic results from a 7-day dosing study to treat PTSD, using its new formulation of BNC210. De...

1 day, 18 hours ago

2 min read